Faropenem

Summary

Faropenem (CHEMBL556262) is a phase-3 clinical-stage small molecule (ATC J01DI03); indicated across 4 conditions including pneumonia and bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01DI03
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 285.32 Da · C12H15NO5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL556262
Name	Faropenem
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65894
ChEBI	CHEBI:51257
ATC	J01DI03
Molecular formula	C12H15NO5S
Molecular weight	285.32
InChIKey	HGGAKXAHAYOLDJ-FHZUQPTBSA-N

SMILES: C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)[C@H]3CCCO3)C(=O)O)O

IUPAC name: (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Also known as: Faropenem, Fropenem, faropenem, FAROPENEM, SID144205728, SID170466271, Faropenem sodium hemipentahydrate

Parent form; salt/anhydrous children: CHEMBL431753

Patent coverage: 982 distinct patent families (3,553 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
pulmonary tuberculosis	2	MONDO:0006052	EFO:1000049
tuberculosis	1	MONDO:0018076	MONDO:0018076

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06804096	PHASE4	RECRUITING	Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
NCT01937832	PHASE3	UNKNOWN	A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
NCT02349841	PHASE2	COMPLETED	Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
NCT02381470	PHASE2	COMPLETED	Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
NCT02393586	PHASE1	COMPLETED	Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).